Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | F12 | P00748 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17040259 | 0.81 | LMNA (0.57) | POLBLMNAKDM4EALDH1A1F2 | |
| SCHEMBL9566416 | 0.80 | LMNA (0.59) | POLBHSD17B10USP2LMNAKDM4E | |
| SCHEMBL11591966 | 0.78 | LMNA (0.69) | HSD17B10LMNAALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL8413034 | 0.75 | HDAC1 (0.56) | POLBUSP2LMNAKDM4EALDH1A1 | |
| SCHEMBL10822717 | 0.74 | MAPT (0.59) | POLBMAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL14880542 | 0.73 | TDP1 (0.62) | HSD17B10MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL22064054 | 0.72 | CHRM4 (0.55) | POLBMAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL11591085 | 0.72 | HDAC1 (0.60) | HSD17B10LMNAALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL11591466 | 0.72 | HDAC1 (0.60) | HSD17B10LMNAALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL4651272 | 0.71 | MAPT (1.00) | POLBMAPTKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | FROST BIOLOGIC, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2015127284-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | POLB 615/4885HSD17B10 2581/4885USP2 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.